Elizabeth Li

6.1k total citations
51 papers, 534 citations indexed

About

Elizabeth Li is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Elizabeth Li has authored 51 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Nephrology, 10 papers in Cardiology and Cardiovascular Medicine and 9 papers in Surgery. Recurrent topics in Elizabeth Li's work include Renal function and acid-base balance (12 papers), Dialysis and Renal Disease Management (9 papers) and Climate Change and Health Impacts (4 papers). Elizabeth Li is often cited by papers focused on Renal function and acid-base balance (12 papers), Dialysis and Renal Disease Management (9 papers) and Climate Change and Health Impacts (4 papers). Elizabeth Li collaborates with scholars based in United States, Canada and United Kingdom. Elizabeth Li's co-authors include Yuri Stasiv, David A. Bushinsky, Vandana Mathur, Dawn Parsell, Donald E. Wesson, Navdeep Tangri, Teh‐wei Hu, Michael Ong, Bertram Pitt and Dahlia Garza and has published in prestigious journals such as The Lancet, Blood and Cancer.

In The Last Decade

Elizabeth Li

35 papers receiving 521 citations

Peers

Elizabeth Li
Comparison fields: 5 of 83
  • Nephrology 176
  • Molecular Biology 167
  • Pulmonary and Respiratory Medicine 117
  • Physiology 80
  • Cardiology and Cardiovascular Medicine 62
Huiping Zhao China
Aurélien Mary France
Sergio Teruya United States
Jason M. Kidd United States
Jean Philippe Haymann France
Ravinder Sodi United Kingdom
Claudia Yuste Spain
Mosaab Awad United States
Luciano Colangelo Italy
Daniel W. Ross United States
Huiping Zhao China View profile →
Citations per field, relative to Elizabeth Li
Elizabeth Li · 1×
Citations per year, relative to Elizabeth Li
Elizabeth Li · 1×

Countries citing papers authored by Elizabeth Li

Since Specialization
Citations

This map shows the geographic impact of Elizabeth Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Li more than expected).

Fields of papers citing papers by Elizabeth Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Li. The network helps show where Elizabeth Li may publish in the future.

Co-authorship network of co-authors of Elizabeth Li

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Li. A scholar is included among the top collaborators of Elizabeth Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Li. Elizabeth Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Title Journal Authors Indexed citations
1 Lived experience of pilonidal sinus disease: Systematic review and meta‐ethnography Colorectal Disease Daniel Baker, Elizabeth Li et al. 0
2 L-5-[11C]-glutamine PET of breast cancer: Preclinical studies in mouse models Nuclear Medicine and Biology Christopher T. Hensley, Prashanth K. Padakanti et al. 0
3 VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis Journal of the American Society of Nephrology Navdeep Tangri, Vandana Mathur et al. 7
4 Uncertainties and opportunities in delivering environmentally sustainable surgery: the surgeons' view Anaesthesia Christina George, James Glasbey et al. 6
5 Environmentally sustainable surgical systems BMJ Global Health Adewale Adisa, Christina George et al. 2
6 Development of a risk of bias assessment tool specifically for meta-analysis of trials for surgical site infection Sivesh K. Kamarajah, Elizabeth Li et al. 0
7 Component separation repair of incisional hernia: evolution of practice and review of long-term outcomes in a single center Hernia Bryar Kadir, Elizabeth Li et al. 0
8 Toward a better understanding of barriers to wayfinding technology use for people with disabilities Assistive Technology Edward Leung, Elizabeth Li et al. 1
9 Implementation of a batched stepped wedge trial evaluating a quality improvement intervention for surgical teams to reduce anastomotic leak after right colectomy Trials Mary L Venn, Charles H. Knowles et al. 3
10 98P Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study Annals of Oncology Shukui Qin, Elizabeth Li et al. 0
11 Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial BMC Nephrology Vandana Mathur, Donald E. Wesson et al. 1
12 Safety and Efficacy of Veverimer in Acidotic Patients With CKD and Heart Failure Kidney International Reports Vandana Mathur, Elizabeth Li et al. 1
13 Effects of Veverimer on Serum Bicarbonate and Physical Function in Patients with Diabetes and CKD: Subgroup Analysis from a Randomized Trial Journal of the American Society of Nephrology Donald E. Wesson, Vandana Mathur et al. 0
14 Effects of Veverimer on Serum Bicarbonate and Physical Function in Elderly Patients with Metabolic Acidosis in CKD Journal of the American Society of Nephrology Donald E. Wesson, Vandana Mathur et al. 0
15 1156O Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821) Annals of Oncology Jingyuan Xu, Lin Shen et al. 2
16 985P A phase II study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond RECIST-defined progression Annals of Oncology Zhenggang Ren, Shukui Qin et al. 1
17 Delayed delivery of endothelial progenitor cell-derived extracellular vesicles via shear thinning gel improves postinfarct hemodynamics Journal of Thoracic and Cardiovascular Surgery Jennifer Chung, Jason J. Han et al. 35
18 Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension The Lancet Donald E. Wesson, Vandana Mathur et al. 62
19 Respuesta a la quimioterapia neoadyuvante (QTneo) según los subtipos intrínsecos determinados por inmunohistoquímica (IHQ) en pacientes con cáncer de mama Gaceta Médica de México Elizabeth Li et al. 1
20 The effects of economic reform on health insurance and the financial burden for urban workers in China Health Economics Teh‐wei Hu, Michael Ong et al. 40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026